Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia - PACE-CME

Updates in the ESCEAS guidelines for the management of dyslipidemia

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
AHA 2024
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Early and sustained non-HDL-c target achievement after MI
Early and sustained non-HDL-c target achievement after MI
Hyperlipidemia
Early and sustained non-HDL-c target achievement after MI
- Jessica Schubert, MD
The remaining challenges in lowering LDL-c in patients at increased CV risk
The remaining challenges in lowering LDL-c in patients at increased CV risk
MinuteCE®
The remaining challenges in lowering LDL-c in patients at increased CV risk
0.75 program credits
- Prof. Kausik Ray
0.75 program credits